Biocon Ltd

Biocon Summary Chart Analysis Peers Quarters Profit & Loss Balance Sheet Cash Flow Ratios Investors Documents

Biocon Ltd

₹ 333 -2.22%
22 May - close price
biocon.com BSE: 532523 NSE: BIOCON
About

Biocon is engaged in the business of manufacture of biotechnology products and research services.(Source : 202003-01 Annual Report Page No:195)

Key Points

Business Segments
1) Biosimilars (58% in FY25 vs 50% in FY23): [1] [2] Biocon Biologics develops and markets a range of 20 biosimilars including insulins, monoclonal antibodies, and conjugated recombinant proteins across diabetology, oncology, immunology, ophthalmology, and other non-communicable diseases. [3] It is one of the top 5 global players in biosimilars and among the top 3 in insulins. It ranks in the top 15 companies worldwide for biomanufacturing capacity and has a presence in 120+ countries, including the U.S., Europe, and emerging markets. Its product portfolio includes 10 approved biosimilars and 10 under development. [4]

The segment revenue grew by 2% YoY in FY25, driven by market share gains in the U.S. and key tender wins in the Emerging Markets. [5]

Website BSE NSE
  • Market Cap ₹ 39,980 Cr.
  • Current Price ₹ 333
  • High / Low ₹ 405 / 270
  • Stock P/E 41.6
  • Book Value ₹ 180
  • Dividend Yield 0.15 %
  • ROCE 6.13 %
  • ROE 4.64 %
  • Face Value ₹ 5.00
Edit ratios

Pros

  • Company has been maintaining a healthy dividend payout of 19.9%

Cons

  • Company has a low return on equity of 4.89% over last 3 years.
  • Company might be capitalizing the interest cost
  • Earnings include an other income of Rs.1,305 Cr.
  • Working capital days have increased from 55.2 days to 77.7 days

* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.

Peer comparison

Sector: Pharmaceuticals Industry: Pharmaceuticals - Indian - Bulk Drugs & Formln

Part of BSE 500 BSE Healthcare BSE 200 Nifty 500 BSE MidCap

Edit Columns
Loading peers table ...

Quarterly Results

Consolidated Figures in Rs. Crores / View Standalone

Mar 2022 Jun 2022 Sep 2022 Dec 2022 Mar 2023 Jun 2023 Sep 2023 Dec 2023 Mar 2024 Jun 2024 Sep 2024 Dec 2024 Mar 2025
2,409 2,140 2,320 2,941 3,774 3,423 3,462 3,954 3,917 3,433 3,590 3,821 4,417
1,870 1,783 1,877 2,352 2,817 2,741 2,745 3,051 3,004 2,812 2,905 3,070 3,339
Operating Profit 539 356 442 589 957 681 717 903 913 620 685 752 1,078
OPM % 22% 17% 19% 20% 25% 20% 21% 23% 23% 18% 19% 20% 24%
26 78 48 -193 152 94 134 587 40 1,166 58 53 57
Interest 10 20 30 120 249 233 248 267 227 236 226 223 212
Depreciation 212 218 231 301 364 358 389 414 407 405 420 425 436
Profit before tax 342 197 229 -26 497 184 214 808 319 1,146 98 156 487
Tax % 17% 15% 64% -19% 17% 19% 19% 7% 30% 25% 72% 48% 6%
284 167 82 -21 414 149 173 753 223 862 27 81 459
EPS in Rs 1.99 1.20 0.39 -0.35 2.61 0.84 1.05 5.50 1.13 5.49 -0.13 0.21 2.87
Raw PDF

Profit & Loss

Consolidated Figures in Rs. Crores / View Standalone

Mar 2014 Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025
2,877 3,090 3,347 3,891 4,123 5,514 6,300 7,143 8,184 11,174 14,756 15,262
2,190 2,394 2,957 2,912 3,294 4,121 4,725 5,562 6,391 8,762 11,540 12,095
Operating Profit 687 696 390 980 829 1,394 1,575 1,581 1,793 2,412 3,216 3,166
OPM % 24% 23% 12% 25% 20% 25% 25% 22% 22% 22% 22% 21%
56 158 639 173 228 340 228 260 72 18 853 1,305
Interest 2 9 29 26 62 71 65 58 68 419 974 897
Depreciation 204 221 249 277 385 448 552 715 814 1,113 1,569 1,687
Profit before tax 538 624 751 850 610 1,215 1,186 1,068 983 897 1,525 1,887
Tax % 20% 15% 19% 19% 26% 17% 27% 21% 22% 28% 15% 24%
431 528 609 688 453 1,003 871 846 772 643 1,298 1,429
EPS in Rs 3.45 4.14 4.59 5.10 3.10 7.54 6.24 6.17 5.40 3.85 8.52 8.44
Dividend Payout % 24% 20% 18% 10% 16% 7% 0% 0% 9% 39% 6% 15%
Compounded Sales Growth
10 Years: 17%
5 Years: 19%
3 Years: 23%
TTM: 3%
Compounded Profit Growth
10 Years: 9%
5 Years: 7%
3 Years: 10%
TTM: -3%
Stock Price CAGR
10 Years: 16%
5 Years: -1%
3 Years: 0%
1 Year: 8%
Return on Equity
10 Years: 7%
5 Years: 6%
3 Years: 5%
Last Year: 5%

Balance Sheet

Consolidated Figures in Rs. Crores / View Standalone

Mar 2014 Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025
Equity Capital 100 100 100 100 300 300 600 600 600 600 600 600
Reserves 2,927 3,171 3,934 4,738 4,881 5,798 6,106 7,027 7,832 17,267 19,183 21,044
864 1,117 2,478 2,302 2,264 2,422 2,715 4,481 5,147 18,019 16,277 18,362
1,860 1,988 1,947 2,254 2,545 3,672 4,993 6,382 6,763 15,856 19,693 18,791
Total Liabilities 5,751 6,375 8,458 9,394 9,990 12,192 14,414 18,490 20,342 51,742 55,753 58,797
1,525 1,630 1,748 3,626 3,700 4,471 5,971 6,364 6,569 29,468 30,644 36,370
CWIP 1,206 1,677 2,240 839 1,303 1,899 2,196 2,800 4,110 7,317 7,993 4,102
Investments 765 230 902 1,253 675 1,012 966 1,952 1,588 2,069 1,000 1,127
2,255 2,839 3,569 3,676 4,312 4,811 5,281 7,374 8,074 12,888 16,117 17,199
Total Assets 5,751 6,375 8,458 9,394 9,990 12,192 14,414 18,490 20,342 51,742 55,753 58,797

Cash Flows

Consolidated Figures in Rs. Crores / View Standalone

Mar 2014 Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025
561 211 371 640 662 1,155 1,283 1,160 1,177 1,852 2,954 4,061
-904 -491 -1,138 -510 -684 -703 -1,505 -3,651 -1,662 -14,260 -1,002 -234
426 186 1,068 -178 -240 -242 388 2,564 242 13,049 -2,333 -1,854
Net Cash Flow 83 -94 300 -47 -261 210 165 72 -243 641 -380 1,973

Ratios

Consolidated Figures in Rs. Crores / View Standalone

Mar 2014 Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025
Debtor Days 76 91 78 83 94 86 71 77 92 117 154 131
Inventory Days 116 132 153 160 161 199 263 304 309 423 368 346
Days Payable 107 125 172 187 224 231 243 246 216 383 467 460
Cash Conversion Cycle 85 98 59 57 31 53 91 134 184 157 55 18
Working Capital Days -0 12 31 34 18 15 8 80 112 85 2 78
ROCE % 15% 12% 9% 12% 8% 13% 12% 10% 9% 6% 6% 6%

Shareholding Pattern

Numbers in percentages

Jun 2022Sep 2022Dec 2022Mar 2023Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025
60.64% 60.64% 60.64% 60.64% 60.64% 60.64% 60.64% 60.64% 60.64% 60.64% 60.64% 60.64%
16.31% 15.79% 14.42% 10.20% 9.52% 7.97% 6.55% 5.63% 5.90% 5.93% 5.66% 5.67%
7.72% 7.76% 8.63% 11.89% 12.59% 14.08% 14.51% 13.69% 14.29% 14.44% 15.36% 15.73%
14.60% 15.17% 15.74% 16.70% 16.77% 16.92% 17.96% 19.74% 18.90% 18.74% 18.11% 17.77%
0.73% 0.63% 0.58% 0.55% 0.49% 0.39% 0.33% 0.32% 0.28% 0.25% 0.22% 0.21%
No. of Shareholders 3,41,0163,69,8163,91,3824,11,0864,12,4414,15,0464,34,3394,70,2614,43,5134,39,5034,27,7054,24,297

* The classifications might have changed from Sep'2022 onwards. The new XBRL format added more details from Sep'22 onwards.

Classifications such as banks and foreign portfolio investors were not available earlier. The sudden changes in FII or DII can be because of these changes.

Click on the line-items to see the names of individual entities.

Documents

Announcements

Annual reports

DRHP

Credit ratings

Concalls